Subject Index

A
Age, effect of on survival, 148
Agglutinins, red cell cold, 341
Alkaline phosphatase, interrelationships of plasma parathyroid hormone and, 404
Allograft rejection, lymphocyte dependent antibody and human chronic renal, 179
Allotransplantation, tubular histuria and serum proteinuria following human kidney, 159
Aluminium intoxication, cause of dialysis dementia?, 355
Anephric man, renin-angiotensin system in, 495
Angiotensin blockade as rapid diagnostic test in hypertension, 506
Angiotensin II and its metabolites, 497
Angiotensin II blockade in hypertension of chronic haemodialysis patients, 513
Angiotensin II measurements, concurrent renin and, 496
Angiotensin II metabolic clearance rate, 497
Antibodies, antinuclear, 344
Antibody, lymphocyte dependent, and human chronic renal allograft rejection, 179
Anti-N-like cold agglutinins in RDT patients, 333
Anti-N-like phenomenon, 344
Antinuclear antibodies, 344
Antirachitic hormones, metabolism of, 574
Arterial complications of 500 renal transplants, 186
Ascites, treatment of during regular dialysis with intraperitoneal colloidal chronic phosphate, 364
Australian transplantation survey, 129

Auto-antibodies, dialysis associated with, 339
Azathioprine withdrawal, effect of, 197

B
Bead charcoal, wide spectrum adsorption capacity of, 265
Blood loss during maintenance dialysis, comparative evaluation of iatrogenic sources of, 233
Blood pressure, dialysis, ultrafiltration and, 293
Blood volume, residual, and Hoeltzenbein dialyser, 327
Bone disease in patients on haemodialysis, plasma immunoreactive calcitonin and, 403
Bone histology, relationship of plasma immunoreactive calcitonin and parathyroid hormone, 405
Bone turnover, decreased, after nephrectomy, and possible mediation by endogenous calcitonin, 409
Brain, histopathology of, 350

C
Charcoal, bead, wide spectrum adsorption capacity of, 265
Charcoal, petroleum-based activated, for direct haemoperfusion, 250
Charcoal capillary haemoperfusion system, 242
Charcoal haemoperfusion and acetate-free dialysate in ten patients with hepatic
coma, efficacy of petroleum, 262
14C-acetate, metabolic fate of during dialysis, 394
Calcitonin, and bone disease in patients on haemodialysis, plasma immunoreactive, 403
Calcitonin, endogenous, and decreased bone turnover after nephrectomy, 409
Calcium transport, 571
Cancer in renal allograft recipients, 133
Carbohydrate absorption, 566
Carbohydrate, protein and fat absorption in chronic uraemia, 566
Cardiac interaction of parathyroid hormone and propranolol in uraemia, 464
Cellular immune responses, studies of, in patients with minimal change nephropathy, 533
Children
age at start of treatment, 63
body growth and skeletal maturation, 84
causes of death, 76
contribution of transplantation, 75
dialysis details, 76
hepatitis, 78
home dialysis, 72
number of dialysis centres, 64
number of patients, 60
on chronic haemodialysis, plasma lipid abnormalities in, 385
primary renal disease, 73
pubertal development, 101
rehabilitation, 78
renal osteodystrophy, 82
survival on regular dialysis and after transplantation, 70
Colloidal chromic phosphate, treatment of ascites during regular dialysis treatment with intraperitoneal, 364
Cytotoxic effector cells, defects in, in long-term renal transplant recipients, 171
Cytotoxicity, direct lymphocyte-mediated, 534, 535
Diabetic patients, maintenance dialysis in, 377
1,25-dihydroxy-vitamin D3, evidence that 1α-hydroxy-vitamin D3 is converted to, before acting in normal and uraemic man, 417
Dialysate
in ten patients with hepatic coma, efficacy of petroleum charcoal haemoperfusion and acetate-free, 262
long-term experience of home dialysis with sorbent regeneration of, 275
Dialysers, re-use of, 43
Dialysis
home, 18
long-term experience of with sorbent regeneration of dialysate, 275
conventional, with maximum ultrafiltration, 295
in Europe, changing pattern of, 39
transplantation in Europe, combined report on regular, 3
maintenance, comparative evaluation of iatrogenic sources of blood loss during, 233
maintenance, in diabetic patients, 377
metabolic fate of 14C-acetate during, 394
nine-hour peritoneal, three times weekly, 306
sorbent peritoneal initial clinical trials, 284
survival: short versus long, 44
three-hour maintenance, combining direct haemoperfusion and haemodialysis, 257
ultrafiltration and blood pressure, 293
Dialysis and transplantation, worldwide comparison of, 9
Dialysis associated with autoantibodies, 335
Dialysis centres and stations, number of, 4
Dialysis dementia, aluminium intoxication the cause of?, 355
Dialysis encephalopathy syndrome, 348
Dialysis patients, causes of death in, 34
Dialysis programme, home, effect of renal transplant on, 143
Dialysis treatment, regular, treatment of ascites during, with intraperitoneal colloidal chromic phosphate, 364
Dialysis units, survey of UK, 353
Dietary factors in renal insufficiency, 573
Dietary intake, relationship with plasma lipid abnormalities in children on chronic haemodialysis, 385
DNA-synthesis, lymphocyte enzymes of, in chronic renal failure, 528

D

Deafness, uraemic, effect of renal transplantation on, 211
Diabetes
medical complications, 380
surgical procedures, 380
visual complications, 177
Diabetes mellitus, atypical glomerular disease in, 546
Diabetic control, 378
Diabetic neuropathy, 177
Donor organs, access to, 123
Drug conjugation, decreased, as a pathogenic factor in the etiology of analgesic nephropathy, 443
Drug distribution in renal disease, 611
Drug metabolism
  in uraemia, 617
  increased, in chronic renal failure, 624
Drugs
  active transport, 613
  dosage of in patients with renal disease, 603
dosage rules, 608
limits of validity, 610
lipid soluble, 599
physical-chemical properties, 612
regional blood flow and, 614
tissue and plasma protein binding of, 614
water soluble, 598

E

Encephalopathy syndrome, dialysis, 348
Excretion of middle molecules, accumulation and, 481
Exocrine pancreatic function in chronic renal failure, 585

F

Fat absorption, 569
Formaldehyde and the occurrence of anti-N-like cold agglutinins in RDT patients, 333

G

Glomerular disease in diabetes mellitus, atypical, 546
Glomerulonephritis
  polymorphonuclear leukocyte enzyme activity in human, 541
  site of sodium retention in, 520
Graft failure, 132
Graft survivals in kidney transplantation, factors influencing patient and, 134
Graft tolerance, effect of HBs antigenaemia on early, 197
Grafts, second and third, 131
Guinea-pig hearts, effects of uremic compounds on oxygen consumption and mechanical activity of isolated, 472

II

Haemagglutination inhibition in vitro studies, 341
Haemodialysis
  alternative to conventional, 306
  cognitive function in patients on, 353
  plasma immunoreactive calcitonin and bone disease in patients on, 403
  plasma lipid abnormalities in children on chronic, 385
  wrist-watch-size single-needle clamping device, 225
Haemodialysis patients
  angiotensin II blockade in hypertension of chronic, 513
  treatment with \( \alpha \)-hydroxycholecalciferol, 434
Haemoglobin synthesis, middle molecules and, 371
Haemoperfusion, petroleum-based activated charcoal for direct, 250
Haemoperfusion and haemodialysis, three-hour maintenance dialysis combining, 257
Haemoperfusion system, charcoal capillary, 282
HBs antigenaemia, role of, in liver disease after renal transplantation, 193
Hepatic coma, efficacy of petroleum charcoal haemoperfusion and acetate-free dialysate in ten patients with, 262
Hepatic failure, absorption of substances elevated in patients with, 265
Hepatitis B, 1975, 47
Hoefitzgenbein dialyser, seventeen months' experience with in paediatric patients, 322
Home dialysis, 18
  long-term experience with sorbent regeneration of dialysate, 275
Home dialysis programme, effect of renal transplantation on a, 143
\( ^3 \)H-uridine incorporation by mouse erythrocyte cells, effect of human uremic plasma on prostoglandin-stimulated, 451
\( \alpha \)-hydroxycholecalciferol in treatment of haemodialysis patients with, 434
renal osteodystrophy, 424
\( \alpha \)-hydroxy-vitamin D3 before acting in normal and uremic man, evidence of, 417
25-hydroxy-vitamin D levels in the nephrotic syndrome, 457
Hypertension, angiotensin blockade as rapid diagnostic test in, 506

643
I
Iatrogenic sources of blood loss during maintenance dialysis, comparative evaluation of, 233
Intestinal absorption in uraemia, 555
Intestinal calcium absorption, 25-OHD$_3$ and parathyroid hormone at different stages of renal insufficiency, 571

K
Kidney, human, allotransplantation, tubular histuria and serum-proteinuria following, 159
Kidney grafts, selection of recipients for, 122
Kidney transplantation, factors influencing patient and graft survivals in, 134
Kidney ultrafiltration, treatment of chronic uraemia by, 314
Kinetics, elimination, and dosage of drugs in patients with renal disease, 603

L
Leukocyte migration inhibition in relapse and remission, 537
Leukocyte migration test, 534, 535
Liver disease after renal transplantation, role of HB$_3$ antigenemia in, 193
Lung infections, opportunistic, in renal transplantation patients, 206
Lymphocyte dependent antibody and human chronic renal allograft rejection, 179
Lymphocyte enzymes of DNA-synthesis in chronic renal failure, 528

M
Magnesium, in renal insufficiency, 573
Metabolic fate of $^{14}$C-acetate during dialysis, 394
Micropuncture, 522, 524
Middle molecules accumulation and excretion of, 481 and haemoglobin synthesis, 371
Mouse erythroid cells, effect of human uraemic plasma on prostaglandin-stimulated $^3$H-uridine incorporation by, 451

N
N-acetyl-para-aminophenol analysis, 444
Natriuretic factor of renal origin, role of a, 520
Necro-kidney transplantation, permanent withdrawal of prednisone in, 216
Necrosis, acute tubular, 112
Nephrectomy, decreased bone turnover after, and possible mediation by endogenous calcitonin, 409
Nephropathy analgesic, decreased drug conjugation as a pathogenic factor in the aetiology of, 443
minimal change, studies of cellular immune responses in patients with, 533
Nephrotic syndrome, 25-hydroxy-vitamin D levels in the, 457
Neurological syndrome clinical description of, 348
drug therapy and dialysate, 352
Neuropathy, uraemic, 109
New Zealand transplantation survey, 129

O
Osteodystrophy, renal, 1,25-hydroxycholecalciferol in the treatment of renal, 424
Oxygen consumption and mechanical activity of isolated guinea-pig hearts, effects of uraemic compounds on, 472

P
Paediatric patients, seventeen months' experience with the Hoeltzenbein dialyser, 322
Parathyroid hormone and propranolol in uraemia, cardiac interaction of, 464
secretion and metabolism of, 575
Patients, number of on the dialysis registry, 3
Peritoneal dialysis, nine-hour, three times weekly, 306
Pharmacology, a child's guide to clinical, in renal failure, 597
Plasma immunoreactive calcitonin and bone disease in patients on haemodialysis, 403
Plasma lipid abnormalities in children on chronic haemodialysis: relationship to dietary intake, 385
Plasma lipids and dietary intake, correlation between, 388
Plasma renin, and plasma angiotensin II concentrations, correlation between, 498
Plasma renin concentration, 497
Polymorphonuclear leukocyte enzyme activity in human glomerulonephritis, 541
Prednisone, permanent withdrawal of in necro-kidney transplantation, 216
Prostaglandin-stimulated 3H-uridine incorporation by mouse erythroid cells, effect of human uraemic plasma on, 451
Protein absorption, 568

R
RDT patients, formaldehyde and the recurrence of anti-N-like cold agglutinins in, 333
Recirculation dialysis with RP6, 298
Red cell cold agglutinins, 341
Rehabilitation, 49
Rejection
aute, 162
lymphocyte-dependent antibody and human chronic renal allograft, 179
Renal allograft recipient, cancer in, 133
Renal allograft rejection, chronic, lymphocyte-dependent antibody and human, 179
Renal disease
drug distribution in, 611
elimination kinetics and dosage of drugs in patients with, 603
primary, 22
Renal failure
a child’s guide to clinical pharmacology in, 597
chronic, exocrine pancreatic function in, 585
chronic, transplantation as method of choice for treatment of, 121
increased drug metabolism in chronic, 624
lymphocyte enzymes of DNA-synthesis in chronic, 528
Renal insufficiency
intestinal calcium absorption, 25-OHD3 and parathyroid hormone at different stages of, 571
pathological changes in pancreas and intestine in, 556
Renal osteodystrophy, 1-α-hydroxycholecalciferol in the treatment of, 424
Renal transplant recipients, defect in cytotoxic effector cells in long-term, 171
Renal transplantation
as method of choice for chronic renal failure, 121
effect of on home dialysis programme, 143
effect of on uraemic deafness, 211
outcome of, 152
role of HB3 antigenaemia in liver disease after, 193
urinary tract infection after, and localisation studies, 200
Renal transplantation patients, opportunist lung infections in, 206
Renal transplants, arterial complications of, 186
Renin and angiotensin II measurements, concurrent, 496
Renin-angiotensin system in anephric man, 495
Renin concentration, plasma, 497
Renin-substrate, 497

S
Saline and angiotensin II, response to infusion of, 496
Serum, alteration of leukocyte migration by autologous, 536
Serum proteinuria, tubular histiocyte area and, following human kidney allotransplantation, 159
Single-needle clamping device, wrist-watch-size, in haemodialysis, 225
Sodium depletion, 498
Sodium depletion experiments, 496
Sodium retention in glomerulonephritis, site of, 520
Solute removal, Hoeftzenbein dialyser, 325
Sorbet peritoneal dialysis, initial clinical trials, 284
Survival, effect of age on dialysis patients, 148
Survival rates, comparison of in individual countries, 12

T
Transplantation, contribution of, 29
Transplantation survey, Australian and New Zealand, 129
Transplanted patients, causes of death in, 38
Transplants, kidney, factors influencing patient and graft survivals in, 134
Transplants, renal
arterial complications of, 186
as method of choice for treatment of chronic renal failure, 121
effect of on a home dialysis programme, 143
outcome of, 152
Tubular histuria and serum proteinuria following human kidney allotransplantation, 159
Tubular necrosis, acute, 162

U
Ultrafiltration, dialysis and blood pressure, 293
Ultrafiltration kidney, treatment of chronic uremia by, 314
Uraemia
cardiac interaction of parathyroid hormone and propranolol in, 464
chronic, carbohydrate, protein and fat absorption in, 566
drug metabolism in, 617
intestinal absorption in, 555
treatment of chronic by an ultrafiltration kidney, 314
Uraemic compounds, effects of on oxygen consumption and mechanical activity of isolated guinea-pig hearts, 472
Uraemic man, evidence that 1α-hydroxy-vitamin D₃ is converted to 1,25-dihydroxy-vitamin D₃ before acting in, 417
Uraemic deafness, effect of renal transplantation on, 211
Uraemic neuropathy, 109
Uraemic plasma, effect of human on prostaglandin-stimulated ³H-uridine incorporation by mouse erythroid cells, 451
Urinary infections, in vitro deconjugating activity of organisms isolated from, 445
Urinary tract infections after renal transplantation and localisation studies, 200
effects of on urinary NAPA rates, 445
Urine, free: total N-acetyl-para-aminophenol ratio in normal subjects and patients with analgesic nephropathy, 445

V
Vascular access, 44

W
Water removal, Hoeltzenbein dialyser, 326